The Cremins lab investigates the epigenetic mechanisms regulating development and function of the mammalian central nervous system. We map and analyze neuronal epigenomes in three-dimensions using quantitative, genome-wide technologies. We also perturb epigenomes by employing state-of-the art genetic engineering strategies (e.g. CRISPR/Cas9, optoepigenetics). To test our hypotheses, we primarily use embryonic and induced pluripotent stem cell models of neuronal differentiation and disease. Our long-term goal is to discover how genome architecture controls genome function, applying this to study fundamental mechanisms controlling neuronal phenotype and, by extension, the onset and progression of neurodegenerative and neurodevelopmental disease states.

Jennifer presents the lab’s work at the Evolution and 
Function of higher-order chromosomes meeting at the Institut Pasteur in 
Paris France.

Jennifer presents the lab’s work at the European Molecular 
Biology Laboratory in Heidelberg, Germany.

Ji Hun Kim travels to Greece to present a podium talk on his 
Light Activated Dynamic Looping technology. Congratulations Ji Hun!

Jennifer presents the lab’s work at the University of Chicago.

Jennifer presents the lab’s work at the University of Virginia 
Medical School Annual Symposium: Higher-order structure and disease.

Deepak Mani joins the lab for his first rotation in the Bioengineering graduate program in Fall 2019. Welcome Deepak!

Jennifer presents the lab’s work at the Company of 
Biologists Epigenetics Meeting in Sussex UK.

Thomas Gilgenast successfully defends his thesis proposal.

Alexandria Nikish joins the lab for her Ph.D. studies in Fall 2019. Ali
did her undergraduate degree at MIT and worked at the Broad Institute as 
well as CRISPR Therapeutics. Welcome, Ali!

logos  

 

Our work is supported by the New York Stem Cell Foundation, the Alfred P. Sloan Foundation, the National Science Foundation, an NIH New Innovator Award through the National Institute of Mental Health and the NIH 4D Nucleome Common Fund Initiative.